Abstract: Deficiency or inhibition of tumor necrosis factor (TNF) significantly prolongs hepatic expression of recombinant adenoviral vectors. To explore mechanisms responsible for this observation, the present studies examined the effects of TNF versus TNF receptor 1 (TNFR1) or TNFR2 deficiency on the course of antiviral-immune responses to a replication-deficient, ␤-galactosidaseencoding recombinant adenovirus (AdCMV-lacZ). Clearance of AdCMV-lacZ was significantly delayed in TNF-deficient mice. Less pronounced but significant delays in AdCMV-lacZ clearance were observed in TNFR2-deficient but not TNFR1-deficient mice. Numbers of interferon-␥ expressing intrahepatic lymphocytes (IHL) were similar in Ad-CMV-lacZ-infected, TNF-deficient, TNFR1-deficient, TNFR2-deficient, and control mice. However, IHL isolated from AdCMV-lacZ-infected, TNF-deficient or AdCMV-lacZ-infected, TNFR2-deficient mice exhibited decreased levels of FasL expression and adenovirus-specific cytolytic T lymphocyte (CTL) activity. Similar defects in allo-specific killing of Fas-sensitive hepatocyte targets by TNF-deficient or TNFR2-deficient but not TNFR1-deficient CTL were also noted. No defects in generation of allo-specific cytotoxicity directed against perforin-sensitive target cells were noted in TNF-, TNFR1-, or TNFR2-deficient lymphocytes. These findings indicate that TNF/TNFR2 interactions facilitate generation of FasL-dependent CTL effector pathways that play an important role in in vivo antiviral-immune responses in the liver. J. Leukoc. Biol. 74: 000 -000; 2003.
INTRODUCTION
Tumor necrosis factor (TNF) is a primary initiator of innateimmune responses, which in turn, determine the magnitude and course of acquired-immune responses [1] . In addition to the prominent role that TNF plays in initial inflammatory responses to bacterial and parasitic infections, TNF also participates in antiviral immunity. Studies investigating immune responses to hepatitis B virus [2] [3] [4] and recombinant adenoviral infections [5] in the liver have suggested that TNF can directly limit viral replication and gene expression by noncytopathic mechanisms. Diminished clearance of replicationdeficient adenoviral vectors in the presence of TNF inhibition or deficiency has been attributed to the role of TNF in initial inflammatory responses and leukocytic infiltration into the liver early in the course of viral infections [6 -8] . In addition to these effects of TNF during early, innate antiviral responses, the TNF/TNF receptor 1 (TNFR1) signaling pathway has been identified as one of the mechanisms responsible for immunemediated killing of virally infected hepatocytes [9 -11] .
In addition to the proinflammatory and direct antiviral effects of TNF, other actions of TNF during adaptive cellularimmune responses have been noted. TNF/TNFR1 and TNF/ TNFR2 signaling pathways have been found to potentiate T cell proliferation and T helper 1 (Th1) cytokine responses [12, 13] . As clearance of noncytopathic viruses is largely dependent on CD8
ϩ T cell responses [14, 15] , any immunomodulatory effects of TNF on generation of this component of the acquiredimmune response are likely to play an important role in the course of antiviral-immune responses that develop during the course of naturally occurring infection by hepatotropic viruses or following liver-directed gene therapies that use recombinant viral vectors.
The present studies were designed to better define the potential role of TNF, TNFR1, and TNFR2 in antiviral-immune responses. As previously reported [6] , markedly delayed clearance of a ␤-galactosidase-encoding recombinant adenovirus (AdCMV-lacZ) was observed in TNF-deficient mice. Lesspronounced delays in AdCMV-lacZ clearance were also observed in TNFR2-deficient but not TNFR1-deficient mice. In contrast to prior inferences derived from histological assessments [6 -8] , normal total numbers of liver-infiltrating lymphocytes were isolated from TNF-deficient mice following Ad-CMV-lacZ infection. However, defects in generation of FasLdependent cytolytic T lymphocyte (CTL) effector pathways were apparent in intrahepatic CD8 ϩ lymphocytes isolated from AdCMV-lacZ-infected, TNF-deficient, or TNFR2-deficient recipient animals, indicating that TNF/TNFR2 interactions play a previously unrecognized role in the development of other cytopathic immune mechanisms in the liver. [16] . Mice used in individual experiments were age-and sex-matched and were used before 12 weeks of age.
MATERIALS AND METHODS

Mice
Adenovirus vectors
The E1-deleted, replication-deficient, ␤-galactosidase-encoding recombinant adenovirus AdCMV-lacZ was propagated in 293 cell cultures and purified on a cesium chloride gradient, and titers of infectious virus were determined by plaque assay as previously described [17] . Mice were injected with 10 9 -10 10 plaque-forming units (PFU) AdCMV-lacZ. In each experiment a constant number of PFU/g body weight were administered to each mouse. Target cells for virus-specific cytotoxicity assays were infected with AdCMV-lacZ at a multiplicity of infection of five to 10 overnight. In other experiments, serum was collected from mice infected with a replication-deficient adenoviral vector encoding a chimeric fusion protein consisting of the extracellular domain of the human 55-kD TNFR linked to the hinge and Fc regions of murine immunoglobulin G1 (IgG1; TNFR-Ig; ref. [18] ). TNFR-Ig or control mouse Ig was purified from the sera by adherence to protein G sepharose (Amersham Pharmacia Biotech AB, Uppsala, Sweden) columns.
␤-Galactosidase assay
␤-Galactosidase activity was quantified by measuring the rate of cleavage of 4-methylumbelliferyl-␤-D-galactoside to yield the fluorescent product 4-methylumbelliferone [19] . Tissue samples were washed in phosphate-buffered saline (PBS). The tissues were then homogenized in a buffer containing 25 mmol/L Tris-HCl at pH 7.5, 125 mmol/L NaCl, and 2 mmol/L MgCl 2 and were then centrifuged at 15,000 g. Then, 40 L supernatant or the supernatant diluted with reaction buffer was incubated at 37ºC for 30 min with 160 L reaction mixture containing 25 mmol/L Tris-HCl at pH 7.5, 125 mmol/L NaCl, 2 mmol/L MgCl 2 , 12 mmol/L 2-mercaptoethanol, and 0.3 mmol/L 4-methylumbelliferyl-␤-D-galactoside (Sigma Chemical Co., St. Louis, MO). The reactions were stopped by adding 50 L 25% trichloroacetic acid. Tubes were cooled on ice for 5-10 min and then centrifuged at high speed for 1-2 min. Thereafter, 100 L supernatant was added to 1.9 mL glycine-carbonate reagent. Light emission at 460 nm after excitation at 365 nm was compared with emission by standard concentrations of 4-methyl-umbelliferone purchased from Sigma Chemical Co.
Protein assay
Protein concentrations in tissue homogenates were assayed by the bicinchoninic acid method using reagents purchased from Pierce Chemical Co. (Rockford, IL) and using bovine serum albumin as a standard [20] .
Isolation of hepatocytes and [
H] thymidine labeling
Anesthetized mice underwent laparotomy, and a catheter was introduced into the inferior vena cava through the right atrium. The portal vein was then severed, the catheter connected to a peristaltic pump, and the liver perfused at 5 mL/min for 2 min with preperfusion buffer: NaCl (0.14 M), KCl (5.4 mM), Na 2 HPO 4 (0.8 mM), HEPES (25 mM), EGTA (12.5 mM), sodium pyruvate (2.3 mM), L-glutamine (2.3 mM), D-glucose (0.5 mM), pH 7.4. The liver was then perfused for 10 min with the perfusion medium: NaCl (0.14 M), KCl (5.4 mM), Na 2 HPO 4 (0.8 mM), HEPES (25 mM), sodium pyruvate (2.3 mM), L-glutamine (2.3 mM), D-glucose (0.5 mM), CaCl 2 (2 mM), MgSO 4 (0.8 mM), collagenase A (0.163 U/mL, Boehringer-Mannheim, Mannheim, Germany), and DNAse I (0.004%, Sigma Chemical Co.). The perfused liver was then removed, placed in a sterile dish containing William's medium (Life Technologies, Inc., Gaithersburg, MD), and then passed through a 100-nylon mesh to obtain a single-cell suspension. Hepatocytes were then centrifuged with 50% percoll (Amersham Pharmacia Biotech AB) at 500 rpm for 15 min to separate dead cells. Hepatocytes were cultured in plates coated with 1% collagen type I (Sigma Chemical Co.) in William's medium supplemented with fetal bovine serum (FBS; 10%), HEPES (25 mM), penicillin (100 U/mL), streptomycin (100 g/mL), fungisone (5 g/mL), insulin (10 g/mL), transferrin (10 g/mL), selenous acid (10 ng/mL), dexamethasone (1 M), epidermal growth factor (5 nm/mL), glucagon (0.1 M), somatotropin (10 U/mL), and prolactin (20 mU/mL), all purchased from Sigma Chemical Co. and added to the medium immediately before use. 
Isolation of hepatic lymphocytes
Intrahepatic lymphocytes (IHL) were isolated as previously detailed [9, 21] . Briefly, after intraperitoneal injection with 10 U heparin and CO 2 narcosis, the abdomen was entered under sterile technique, the portal vein cut, and the abdominal portion of the vena cava perfused with 20 mL Ca 2ϩ -and Mg 2ϩ -free PBS preheated to 37ºC. The liver was removed and passed through a 40-mesh screen and then a 300-mesh screen (VWR Scientific, West Chester, PA, cat. #EC587-40 and EC589-300, respectively). The cell suspension was centrifuged with 35% percoll at 1500 rpm for 15 min, and the cell pellet was cultured in a 75-cm 2 flask in complete medium supplemented with 10% FBS (Life Technologies), 100 U/mL penicillin, 1 g/mL gentamycin, and 2 mM L-glutamine (Sigma Chemical Co.) for 4 h. Then, the lymphocytes were aspirated and centrifuged again with 35% percoll. Afterwards, cells were used as effectors in cytotoxicity assays or for flow cytometric studies. For assessment of intracellular interferon-␥ (IFN-␥) and FasL expression, cells were incubated in 5% CO 2 , 37ºC incubator with phorbol 12-myristate 13-acetate (50 ng/ml), A23187 (500 ng/ml), and Brefeldin A (10 g/ml) for 4 h. Cells were then labeled with the surface-staining antibodies and fixed with 4% formaldehyde at room temperature for 10 min. After fixation, the cells were incubated on ice for 1 h with saponin-containing medium to permeabilize the membranes. The phycoerythrin (PE)-labeled anti-IFN-␥ (XMG1.2) or PE-labeled anti-Fas ligand (FasL, Jo-2) antibodies were added and incubated at 4ºC for 1 h. This was followed by two washes with saponin-containing medium and one final wash with normal staining medium. The cells were analyzed by fluorescence-activated flow cytometry on a FACScan. Representative dot plot results obtained with these flow cytometric techniques have been published previously [9] .
Flow cytometric analysis
Cell lines
The nontransformed AML-12 hepatocyte cell line (H-2K b, D q , [9] ) and the P815 mastocytoma cell line (H-2 d ) were purchased from ATCC.
Generation of allo-specific CTL
In vitro-activated allo-specific CTL were generated in 5-day monocyte-lineage cells (MLC) containing 10 -12 million responder spleen cells from B6 mice and an equal number of irradiated FVB or DBA/2J spleen cells to generate anti H-2 q -and H-2 d -specific CTL, respectively, as previously described [9, 22] .
Chromium release assay
Targets were labeled with 150 Ci Na 2 CrO 4 for 60 -90 min at 37ºC and washed twice before incubation with the different effectors at different effector: target ratios in 200 L cultures. After 12 or 18 h, 100 L supernatant was harvested from experimental and control wells and the percentage of specific lysis, as calculated from the formula: % Specific lysis ϭ experimental release (cpm) -spontaneous release (cpm)/maximal release (cpm) -spontaneous release (cpm) ϫ 100. Virus-specific cytotoxicity was calculated by subtracting the percent-specific lysis of noninfected targets from percent-specific lysis of infected targets [9, 22] . In some assays, 1 g protein G sepharose-purified TNFR-Ig or control Ig was added to each well of cytotoxicity assays. All the assays were performed in triplicate, and results shown use mean Ϯ SEM.
JAM test for apoptosis (DNA fragmentation)
[ 3 H] Thymidine was added to culture dishes for 12-18 h at a final concentration of 2.5-5 Ci/mL. Targets were harvested and cultured with effector cells as in the chromium release assay. At the end of the assay, cells were aspirated onto fiberglass filters by vacuum suction, DNA dried, and [
3 H] thymidinelabeled high molecular weight DNA quantitated by scintillation counting. The specific DNA fragmentation was determined using the following formula: % Specific DNA fragmentation ϭ control (cpm) -experimental (cpm)/control (cpm) ϫ 100, and control cpm is the total [ 3 H] thymidine retained in absence of effector cells [23] .
Statistical analysis
Comparison between continuous variables was made by nonparametric ANOVA using Sigma Stat (SPSS Inc., Chicago, IL) software.
RESULTS
Delayed clearance of AdCMV-lacZ from livers of TNF-and TNFR2-deficient mice TNF-deficient B6.TNF-/-, TNFR-deficient B6.TNFR1-/-, or B6.TNFR2-/-and control B6 mice were infected with Ad-CMV-lacZ and sacrificed at different time points to assess hepatic expression of the adenoviral transgene product, ␤-galactosidase. As shown by the results detailed in Figure 1 , similar levels of ␤-galactosidase expression were observed in the livers of all four strains of mice at day 3 after AdCMV-lacZ infection. Whereas ␤-galactosidase expression declined over a similar time course in B6 and B6.TNFR1-/-mice, livers of B6.TNF-/-mice detected significantly higher levels of the AdCMV-lacZ transgene product for at least 42 days after adenoviral infection. Furthermore, delayed clearance of Ad-CMV-lacZ also was observed in TNFR2-deficient mice, and significantly higher levels of ␤-galactosidase expression were noted in livers of B6.TNFR2-/-mice than in livers of control or TNFR1-deficient mice, 7 and 21 days after infection (Fig. 1) .
Similar total
T cell numbers but lower numbers of CD8 ϩ T cells infiltrate livers of AdCMV-lacZinfected B6.
TNF-/-mice
To assess the effect of TNF and TNFRs on intrahepatic, antiviral T cell responses, IHL from B6.TNF-/-, B6.TNFR1-/-, B6.TNFR2-/-, and control B6 were isolated, counted, and stained with anti-CD4 and anti-CD8 7 days after AdCMV-lacZ infection. Flow cytometric analysis of IHL revealed a similar increase in the total number of IHL in all strains of mice (Fig. 2, left panel) 7 days after AdCMV-lacZ infection. However, as detailed in Figure  2 (right panel), the absolute number of CD8 ϩ IHL detected in livers of B6.TNF-/-mice 7 days after AdCMV-lacZ infection was significantly lower (PϽ0.001) than the absolute number of CD8 ϩ IHL noted in the other mouse strains.
Intracellular expression of IFN-␥ in intrahepatic CD8
ϩ or CD8 -lymphocytes
In subsequent experiments, IHL from AdCMV-lacZ-infected mice were assessed for cytokine responses. As shown in Figure 3 , when IHL were assessed for IFN-␥ expression, we found that the percentage of CD8 ϩ or CD8 -cells expressing IFN-␥ was similar in all strains (left panels), and the total number of IFN-␥-expressing IHL recovered from each strain and days after AdCMV-lacZ infection, was not significantly decreased in any of the strains with TNF or TNFR deficiency (data not shown). Of interest, however, because of a lower absolute number of CD8 ϩ IHL in the livers of TNF-deficient mice (Fig. 2) , there was a modest decrease in number of IFN-␥-expressing CD8 ϩ cells in these mice (Fig. 3 , upper right), but because of a reciprocal increase in the number of CD8 (-) IFN-expressing IHL in these TNF-deficient mice (Fig.  3, lower right) , the total IFN-␥ response was indistinguishable from that of other strains.
Expression of FasL by intrahepatic CD8
ϩ lymphocytes is decreased in B6.TNF-/-and B6.TNFR2-/-mice
In additional studies, we assessed FasL expression by CD8 ϩ IHL from the various strains of adenovirus-infected mice. As shown in Figure 4 , there was a 50% decrease in the number of FasL-expressing CD8 ϩ IHL in infected, TNF-deficient mice relative to numbers of FasL ϩ CD8 ϩ IHL from infected, control B6 mice. There was also a statistically significant reduction in FasL ϩ CD8 ϩ IHL cells in AdCMV-lacZ-infected B6.TNFR2-/-mice, whereas numbers of FasL ϩ CD8 ϩ IHL from B6.TNFR1-/-mice were similar to those detected in infected B6 mice. Levels of FasL expression CD8 ϩ IHL from infected mice of all strains were significantly higher than in intrahepatic CD8
ϩ lymphocytes from noninfected B6 mice (data not shown).
Virus-specific killing by liver lymphocytes from AdCMV-lacZ-infected mice
To further assess antiviral CTL responses in TNF-and TNFRdeficient mice, lymphocytes were isolated from livers of B6.TNF-/-and control B6 mice 1 week after infection with AdCMV-lacZ and were assessed for adenovirus-specific killing of adenovirus-infected hepatocytes. As illustrated by results of two representative experiments detailed in Figure 5 , IHL from adenovirally infected B6.TNF-/-are less effective in killing AdCMV-lacZ-infected, fresh B6 hepatocytes than IHL from adenovirally infected wild-type B6 mice. As shown in Experiment #2 of Figure 5 , B6.TNFR2-/-IHL also were significantly less-efficient in killing adenovirus-infected B6 hepatocyte target than IHL obtained from adenovirally infected B6 or B6.TNFR1-/-mice. Thus, deficiencies in TNF or TNFR2 were associated with less-efficient generation of CTL, capable of killing adenovirally infected hepatocytes.
Allo-specific killing by splenocytes
To assess whether TNF also plays a role in activation of CTL activated under other experimental conditions, additional experiments were performed in which allo-specific CTL were generated in vitro and assessed for killing of AML-12 hepatocytes or P815 mastocytoma cells. Spleen cells were isolated from B6 mice or mice with TNF, TNFR, perforin, or functional FasL and were then stimulated in vitro for 5 days with irradiated splenocytes from FVB (H-2 q ) mice or DBA/2J (H-2 d ) mice to generate allo-specific CTL. The FVB-stimulated lymphocytes were used to kill H-2D q expressing AML-12 hepatocytes, whereas DBA/2J-stimulated lymphocytes were assessed for killing of H-2 d expressing P815 mastocytoma cells. As illus- 
Fig. 3. IFN-␥ expression in CD8
ϩ or CD8 -IHL following AdCMV-lacZ infection. IHL were isolated from B6 (q), B6.TNF-/-(e), B6.TNFR1-/-(OE), and B6.TNFR2-/-(⅜) mice 7 days after infection with Ad-CMV-lacZ and were double-stained with anti-CD8 and anti-IFN-␥, as detailed in Materials and Methods. The graphs show the percentages (left panels) and the absolute numbers (right panels) expressed as mean Ϯ SEM of three to four determinations per strain.
trated by the results of the experiments detailed in the left upper panel of Figure 6 , AML-12 hepatocytes are resistant to killing by FasL-defective CTL from B6.gld mice, whereas no decrease in allo-specific killing of this FasL-sensitive hepatocyte target cell line is noted when a TNF inhibitor (TNF-Ig) is added during cytotoxicity assays or when perforin-deficient B6.pfp-/-effector cells are used. In contrast, perforin-deficient CTL are defective in killing of the perforin-sensitive P815 target cells (Fig. 6, upper right panel) , and FasL defects or TNF inhibition have no effects on P815 killing. In additional studies (data not shown), P815 and AML-12 target cells were found resistant to killing by up to 1000 U/ml recombinant TNF and killing of either target cell line by B6 effector cells.
Additional experiments used the selective sensitivity of these target cells to FasL-or perforin-dependent cytotoxicity mechanisms to assess the role of TNF/TNFR interactions in generation of CTL effector function. As shown by the results of representative experiments detailed in the lower panels of Figure 6 , in vitro-activated cytotoxic T cells from TNF-deficient and TNFR2-deficient mice but not from TNFR1-deficient mice were defective in killing FasL-sensitive, perforin, and TNF-resistant AML-12 targets (left lower panel, Fig. 6 ). However, CTL from all mouse strains killed perforin-sensitive and FasL-and TNF-resistant P815 target cells with similar efficiency (lower right panel). Thus, TNF/TNFR2 interactions appear to be important in activating FasL-dependent but not perforin-dependent killing mechanisms.
DISCUSSION
TNF is a pleiotropic cytokine that plays a prominent role in innate-and adaptive-immune responses directed against a variety of microbial agents [1, 24] . In addition to the prominent role that TNF plays in host immunity to various bacterial infections, TNF has also been observed to promote antiviralimmune responses [4 -8] . Previously observed antiviral effects of TNF have been attributed to direct effects on viral replication [4, 5] , to direct killing of virally infected cells [9, 11] , or to indirect effects related to the role that TNF plays in promoting inflammatory responses [6 -8] via induction of expression of adhesion molecules and production of other proinflammatory cytokines. The present studies provide evidence for another pathway, whereby TNF promotes antiviral-immune responses in the liver. Specifically, the results indicate that TNF/TNFR2 interactions are required for optimal generation of CD8 ϩ T cell-effector functions mediated via FasL/Fas-dependent mechanisms, which in turn, play a physiologically significant role in clearance of virally infected hepatocytes [9] .
The present findings are among only a limited number of observations that provide insight into in vivo functions of TNFR2 [25] . Soluble and membrane-bound TNF have similar agonist activity for TNFR1, whereas TNFR2 preferentially responds to membrane-bound TNF. Therefore, it is not surprising that TNF/TNFR1 interactions appear to play a more important role in the proinflammatory and cytotoxic effects of soluble TNF released by macrophages early in the course of innate-immune responses [24, 25] . In contrast, the present findings as well as those from a variety of previous studies support a role for TNF/TNFR2 interactions in adaptive cellular-immune responses. Prior studies have indicated a role for TNF/TNFR2 signaling in thymocyte and T lymphocyte proliferative responses [12, 13, 26] and in promotion of Th1 cytokine responses during major histocompatibility complex class II disparate graft-versus-host disease (GVHD) [12] . Although the present studies are the first to indicate a role for TNF/TNR2 signaling in generation of CD8 ϩ CTL effector function, other 5 . Virus-specific killing of AdCMV-lacZ-infected B6 hepatocyte targets. IHL isolated from B6.TNF-/-(e) and B6 (q) livers 7 days after infection with AdCMV-lacZ were assessed for their ability to kill control or AdCMVlacZ-infected B6 hepatocytes in 18-h assays (Exp #1). Experiment 2 shows the virus-specific killing of B6 hepatocytes by IHL isolated from AdCMV-lacZ-infected B6 (q), B6.TNF-/-(e), B6.TNFR1-/-(OE), and B6.TNFR2-/-(⅜) mice. Virus-specific killing was determined by subtracting the background killing of noninfected control targets from that of infected targets. Results detailed in this figure are representative of three separate experiments assessing killing of AdCMV-lacZ-infected hepatocytes by IHL from each mouse strain.
investigators have also observed a role for TNF in promotion of allo-specific CTL responses during GVHD [27] , and other TNF family members, such as CD70 and LIGHT [homologous to lymphotoxins, exhibits inducible expression, competes with herpes simplex virus glycoprotein D for herpes virus entry mediator (HVEM), a receptor expressed by T lymphocytes], promote generation of CD8 ϩ CTL effector function [22, 28, 29] . Of note, such CTL activation by CD70 and LIGHT is mediated by engagement of TNFR2-like receptors that bind adaptor proteins capable of mediating protein intracellular activation signals. Thus, future studies examining common TNF/TNFR2, CD70/CD27, and LIGHT/HVEM signaling pathways in CD8 ϩ T cells may provide insight into common mechanisms used by TNF/TNFR family members for potentiation of antiviral CTL responses.
Although direct effects of soluble TNF on viral replication and/or virally encoded gene expression have been observed in other viral infection models [4, 5] , the kinetics of AdCMV-lacZ transgene expression observed in the present studies in mice with selective deficiencies in TNF, TNFR1, or TNFR2 argues that TNF has no significant direct, noncytopathic effect on virally encoded gene expression in this experimental model. These differences likely relate to differences in adenoviral cytomegalovirus promoter constructs, as direct effects of TNF on adenoviral vector reporter gene expression have been noted to be promoter-dependent [5] . Prior studies have observed vigorous TNF responses within 24 -48 h of recombinant adenovirus infusion into mice [30, 31] . Yet, 3 days after infection with AdCMV-lacZ, levels of ␤-galactosidase expression in TNF-deficient, TNFR1-deficient, and TNFR2-deficient mice were not significantly different than observed in wild-type B6 mice. Only later in the course of AdCMV-lacZ infection, at time points when adaptive CTL responses had been elicited, were statistically significant differences in levels of adenoviral transgene expression observed in mice with deficiencies in TNF and/or TNFR expression.
It has been postulated previously that impaired intrahepatic antiviral-immune responses in TNF-deficient mice may be related to diminished induction of adhesion molecule expression and secondary decreases in leukocyte migration into the liver of infected animals [6 -8] . However, in the present studies, no decrease in total numbers of IHL was detected in B6.TNF-/-, B6.TNFR1-/-, or B6.TNFR2-/-mice 7 days after AdCMV-lacZ infection, a time point previously found to correspond to the peak of intrahepatic T lymphocyte infiltration and expansion in wild-type B6 mice [9] . These findings suggest that mechanisms other than defects in lymphocyte migration to the liver likely account for previously noted differences in histologic patterns of inflammation found in the livers of adenovirally infected TNF-deficient mice. Of note, in contrast to the absence of inflammatory responses to apoptotic cell death in other organs, induction of hepatocyte apoptosis, as occurs during CTL killing of virally infected hepatocytes, is associated with an inflammatory response characterized histologically by foci of mixed inflammatory cells that accumulate initially at sites of hepatocyte death [32, 33] . In the present studies, diminished intrahepatic CD8 ϩ T cell FasL expression and decreased IHL cytotoxic effector function were noted in TNFdeficient and TNFR2-deficient mice during adenoviral infection. Thus, defects in CTL killing of adenovirally infected hepatocytes and a secondary diminished inflammatory response afford the best explanation for prior reports of diminished foci of inflammatory cell infiltrates and the present observations indicating normal expansion of intrahepatic T lymphocytes in the livers of adenovirus-infected, TNF-deficient mice.
In the present studies, defects in adenovirus clearance were more pronounced in TNF-deficient mice than in mice with selective deficiency of TNFR1 or TNFR2. One potential explanation for this observation is that abnormalities unique to TNF-deficient mice account for more severe defects in antiviral immunity. TNF-deficient and TNFR1-deficient mice exhibit defects in germinal center formation [16, 34] . However, as TNFR1-deficient mice exhibit no delay in adenoviral clearance (present studies), and inhibition of TNF activity by expression of circulating TNF inhibitor proteins in mature, wild-type mice also leads to prolonged adenoviral gene expression comparable with what is observed in TNF-deficient mice [7, 8] , defects in lymphocyte development do not appear to explain impaired antiviral immunity in TNF-deficient animals. An alternative explanation for the present findings is that complementary and overlapping roles of TNF/TNFR1 and TNF/TNFR2 signals in antiviral-immune responses are responsible for the much more severe delay in adenoviral clearance observed in TNF-deficient mice than is observed in animals deficient in only a single TNFR. For instance, in addition to the role for TNF/TNFR2 signaling during T cell activation in generation of FasL-dependent, cell-mediated cytotoxicity, TNF engagement of TNFR1 on hepatocytes represents an independent pathway for cytopathic removal of virally infected hepatocytes [9, 11] . Of note, signaling via TNFR1 and TNFR2 has been reported to be necessary for hepatotoxicity mediated by transmembrane TNF [35] . Finally, TNFR2 signaling has been noted to potentiate FasL-mediated cytotoxicity [36] . Thus, various TNF/TNFR signaling pathways appear to be important in the generation of activated, cytotoxic effector cells and in the effector phase of antiviral immunity, and the additive and synergistic nature of these immune effector mechanisms likely accounts for the much more dramatic impairment of antiviral immunity in TNFdeficient mice than is noted in mice deficient in only a single TNFR.
Although decreases in T cell-proliferative responses and IFN-␥ expression by TNFR1-and TNFR2-deficient T cells have been observed in other experimental models [12, 37, 38] , in the present studies, only modest impairment in expansion of intrahepatic CD8
ϩ T cells was noted in TNF-deficient mice, and no change was in total IHL expansion or IFN-␥ expression. Mice deficient in TNFR1 or TNFR2 exhibited no alterations in intrahepatic T cell expansion or IFN-␥ expression. Yet, in TNF-deficient and TNFR2-deficient mice, impairment of CD8 ϩ T cell FasL expression and FasL-dependent cytotoxicity was apparent. These findings suggest a hierarchy in levels of TNF-mediated, costimulatory signals required for optimal T cell responses in this experimental model, and generation of FasL-dependent CTL effector function is most dependent on TNF costimulation. Such differences in the signaling events needed to generate FasL-dependent CTL effector function versus other T cell effector functions have been reported previously [39] . In summary, the present studies provide evidence for a previously unrecognized role for TNF/TNFR2 interactions in promotion of FasL-dependent CTL effector functions during in vivo antiviral-immune responses in the liver. Prior studies have found hepatocytes to be resistant to killing via perforin-dependent mechanisms [9, 11] and have identified no significant role for perforin in clearance of viral infections from the liver [9] . Thus, it is likely that TNF plays a more prominent role in antiviral-immune responses in the liver, because of the greater dependence on TNF-mediated, TNF-potentiated, cytopathic mechanisms in clearance of viral infections from this organ.
